🚀 VC round data is live in beta, check it out!
ClearPoint Neuro Valuation Multiples
Discover revenue and EBITDA valuation multiples for ClearPoint Neuro and similar public comparables like Universal Vision, Abbott Pakistan, Standard BioTools, Medios and more.
ClearPoint Neuro Overview
About ClearPoint Neuro
ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. The company's products include the ClearPoint system, ClearPoint Services, ClearPoint Disposables, ClearPoint Software, and ClearPoint Therapeutic Solutions.
Founded
1998
HQ
Employees
115
Website
Financials (LTM)
EV
$366M
ClearPoint Neuro Financials
ClearPoint Neuro reported last 12-month revenue of $42M and negative EBITDA of ($16M).
In the same LTM period, ClearPoint Neuro generated $25M in gross profit, ($16M) in EBITDA losses, and had net loss of ($27M).
Revenue (LTM)
ClearPoint Neuro P&L
In the most recent fiscal year, ClearPoint Neuro reported revenue of $37M and EBITDA of ($15M).
ClearPoint Neuro expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $42M | XXX | $37M | XXX | XXX | XXX |
| Gross Profit | $25M | XXX | $23M | XXX | XXX | XXX |
| Gross Margin | 61% | XXX | 61% | XXX | XXX | XXX |
| EBITDA | ($16M) | XXX | ($15M) | XXX | XXX | XXX |
| EBITDA Margin | (37%) | XXX | (41%) | XXX | XXX | XXX |
| EBIT Margin | (58%) | XXX | (65%) | XXX | XXX | XXX |
| Net Profit | ($27M) | XXX | ($26M) | XXX | XXX | XXX |
| Net Margin | (64%) | XXX | (69%) | XXX | XXX | XXX |
| Net Debt | — | — | $3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
ClearPoint Neuro Stock Performance
ClearPoint Neuro has current market cap of $354M, and enterprise value of $366M.
Market Cap Evolution
ClearPoint Neuro's stock price is $11.79.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $366M | $354M | 0.0% | XXX | XXX | XXX | $-0.85 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialClearPoint Neuro Valuation Multiples
ClearPoint Neuro trades at 8.8x EV/Revenue multiple, and (23.5x) EV/EBITDA.
EV / Revenue (LTM)
ClearPoint Neuro Financial Valuation Multiples
As of April 19, 2026, ClearPoint Neuro has market cap of $354M and EV of $366M.
Equity research analysts estimate ClearPoint Neuro's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ClearPoint Neuro has a P/E ratio of (13.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $354M | XXX | $354M | XXX | XXX | XXX |
| EV (current) | $366M | XXX | $366M | XXX | XXX | XXX |
| EV/Revenue | 8.8x | XXX | 9.9x | XXX | XXX | XXX |
| EV/EBITDA | (23.5x) | XXX | (24.1x) | XXX | XXX | XXX |
| EV/EBIT | (15.2x) | XXX | (15.1x) | XXX | XXX | XXX |
| EV/Gross Profit | 14.4x | XXX | 16.1x | XXX | XXX | XXX |
| P/E | (13.3x) | XXX | (13.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (15.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified ClearPoint Neuro Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
ClearPoint Neuro Margins & Growth Rates
ClearPoint Neuro's revenue in the last 12 month grew by 34%.
ClearPoint Neuro's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.4M for the same period.
ClearPoint Neuro's rule of 40 is 12% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ClearPoint Neuro's rule of X is 76% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
ClearPoint Neuro Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 34% | XXX | 43% | XXX | XXX | XXX |
| EBITDA Margin | (37%) | XXX | (41%) | XXX | XXX | XXX |
| EBITDA Growth | 0% | XXX | 9% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 12% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 76% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 45% | XXX | 45% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 40% | XXX | 45% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 34% | XXX | 38% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 127% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
ClearPoint Neuro Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| ClearPoint Neuro | XXX | XXX | XXX | XXX | XXX | XXX |
| Universal Vision | XXX | XXX | XXX | XXX | XXX | XXX |
| Abbott Pakistan | XXX | XXX | XXX | XXX | XXX | XXX |
| Standard BioTools | XXX | XXX | XXX | XXX | XXX | XXX |
| Medios | XXX | XXX | XXX | XXX | XXX | XXX |
| Delcath Systems | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ClearPoint Neuro M&A Activity
ClearPoint Neuro acquired XXX companies to date.
Last acquisition by ClearPoint Neuro was on XXXXXXXX, XXXXX. ClearPoint Neuro acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by ClearPoint Neuro
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialClearPoint Neuro Investment Activity
ClearPoint Neuro invested in XXX companies to date.
ClearPoint Neuro made its latest investment on XXXXXXXX, XXXXX. ClearPoint Neuro invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by ClearPoint Neuro
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout ClearPoint Neuro
| When was ClearPoint Neuro founded? | ClearPoint Neuro was founded in 1998. |
| Where is ClearPoint Neuro headquartered? | ClearPoint Neuro is headquartered in United States. |
| How many employees does ClearPoint Neuro have? | As of today, ClearPoint Neuro has over 115 employees. |
| Who is the CEO of ClearPoint Neuro? | ClearPoint Neuro's CEO is Joseph M. Burnett. |
| Is ClearPoint Neuro publicly listed? | Yes, ClearPoint Neuro is a public company listed on Nasdaq. |
| What is the stock symbol of ClearPoint Neuro? | ClearPoint Neuro trades under CLPT ticker. |
| When did ClearPoint Neuro go public? | ClearPoint Neuro went public in 2012. |
| Who are competitors of ClearPoint Neuro? | ClearPoint Neuro main competitors are Universal Vision, Abbott Pakistan, Standard BioTools, Medios. |
| What is the current market cap of ClearPoint Neuro? | ClearPoint Neuro's current market cap is $354M. |
| What is the current revenue of ClearPoint Neuro? | ClearPoint Neuro's last 12 months revenue is $42M. |
| What is the current revenue growth of ClearPoint Neuro? | ClearPoint Neuro revenue growth (NTM/LTM) is 34%. |
| What is the current EV/Revenue multiple of ClearPoint Neuro? | Current revenue multiple of ClearPoint Neuro is 8.8x. |
| Is ClearPoint Neuro profitable? | No, ClearPoint Neuro is not profitable. |
| What is the current EBITDA of ClearPoint Neuro? | ClearPoint Neuro has negative EBITDA and is not profitable. |
| What is ClearPoint Neuro's EBITDA margin? | ClearPoint Neuro's last 12 months EBITDA margin is (37%). |
| What is the current EV/EBITDA multiple of ClearPoint Neuro? | Current EBITDA multiple of ClearPoint Neuro is (23.5x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.